Bristol Myers Squibb: progress against lung cancer
(CercleFinance.com) - On Saturday Bristol Myers Squibb announced four-year follow-up results from the phase 3 CheckMate -9LA trial demonstrating sustained long-term survival benefits with Opdivo (nivolumab) plus Yervoy (ipilimumab) with two cycles of chemotherapy in patients with metastatic non-small cell lung cancer.
With a minimum follow-up of 47.9 months, the combination of two immunotherapies continued to improve overall survival with 21% of patients treated with Opdivo plus Yervoy with two cycles of chemotherapy alive compared with 16% of patients treated with chemotherapy alone at four years.
With an extended follow-up, the clinically meaningful efficacy benefit was maintained across secondary endpoints and key patient subgroups, with more pronounced benefits among patients with high unmet need.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
With a minimum follow-up of 47.9 months, the combination of two immunotherapies continued to improve overall survival with 21% of patients treated with Opdivo plus Yervoy with two cycles of chemotherapy alive compared with 16% of patients treated with chemotherapy alone at four years.
With an extended follow-up, the clinically meaningful efficacy benefit was maintained across secondary endpoints and key patient subgroups, with more pronounced benefits among patients with high unmet need.
Copyright (c) 2023 CercleFinance.com. All rights reserved.